Nuveen Variable Rate Preferred & Income Fund 最大收入來源為 Point-of-care Testing, Low-dose Interferon Alpha Therapeutics and Synthetic RNA-driven preventative Medicine,在最近的收益報告中收入為 20,729。就地區而言,United States 是 Nuveen Variable Rate Preferred & Income Fund 的主要市場,收入為 20,729。